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Abstract: The nasal route receives a great deal of attention as a non-invasive method for the systemic
administration of drugs. For nasal delivery, specific formulations containing excipients are used.
Because of the sensitive respiratory mucosa, not only the active ingredients, but also additives need
to be tested in appropriate models for toxicity. The aim of the study was to measure the cytotoxicity
of six pharmaceutical excipients, which could help to reach larger residence time, better permeability,
and increased solubility dissolution rate. The following excipients were investigated on RPMI 2650
human nasal septum tumor epithelial cells: β-D-mannitol, sodium hyaluronate, α and β-cyclodextrin,
polyvinyl alcohol and methylcellulose. 3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) dye conversion assay and real-time impedance analysis were used to investigate cytotoxicity.
No excipient showed toxicity at 0.3% (w/v) concentration or below while 1% concentration a
significantly reduced metabolic activity was measured by MTT assay for methylcellulose and
cyclodextrins. Using impedance measurements, only β-cyclodextrin (1%) was toxic to cells. Mannitol
at 1% concentration had a barrier opening effect on epithelial cells, but caused no cellular damage.
Based on the results, all additives at 0.3%, sodium hyaluronate and polyvinyl alcohol at 1%
concentrations can be safely used for nasal formulations.
Keywords: nasal; cytotoxicity; nasal formulation; MTT dye assay; real-time impedance analysis
1. Introduction
Interest in intranasal administration as a non-invasive route for drug delivery continues to
grow rapidly. The high vascularization of the nasal mucosa affords a rapid onset of therapeutic
effect and it can be administered easily by the patient or a physician. There is no hepatic first-pass
metabolism, and nasal preparations do not require sterile preparations. The easy and non-invasive
application maximizes patient comfort and compliance. A large variety of therapeutic compounds
can be delivered intranasally, including relatively large biomolecules such as peptides and proteins,
particularly in the presence of permeation enhancers [1]. Drugs can cross through the nasal mucosal
membrane using two different pathways: transcellularly—across the cell—and paracellular, via the
intercellular tight junctions. Nasal delivery requires special formulations and vehicles [2,3] to achieve
the right bioavability. Excipients, such as absorption enhancers or mucoadhesive polymers, can
increase the drug residence time in the nasal cavity and enhance the absorption [4,5]. Because of the
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sensitiveness of the respiratory mucosa, not only the active ingredients but the additives are needed
to be tested in adequate models for real toxicity data [6]. Our groups have recently optimized a
human nasal epithelial cell based culture model and tested the cellular toxicity of sucrose esters, novel
pharmaceutical additives [7,8].
The aim of our present work was to investigate the effect of the most frequently used excipients on
RPMI 2650 human nasal epithelial cells by two different methods. The colorimetric endpoint MTT dye
conversion assay provided information on the metabolic state of the cells, while real-time monitoring
of impedance showed the biological state of the cell cultures including growth, viability and adherence
without using a tracer. Previous measurements related to this topic cannot be found in the literature.
2. Results and Discussion
Based on the MTT assay, none of the excipients showed toxicity at 0.3% (w/v) concentration
or below on human nasal epithelial cells. At 1% concentration, a highly and significantly reduced
metabolic activity was measured by the colorimetric test of methylcellulose and the cyclodextrins
(Figure 1). This concentration of the excipients was further studied in a kinetic experiment using
impedance measurements.
Molecules 2016, 21, 658 2 of 5 
adequat  models for r al toxicity data [6]. Our groups have recently optimized a human na al pithelial 
cell based culture mod l an  tested the cellular toxicity of sucrose esters, nov l pharmaceutical 
additives [7,8]. 
The aim of our present work was to investigate the effect of the most frequently used excipients 
on RPMI 2650 human nasal epithelial cells by two different methods. The colorimetric endpoint MTT 
dye conversion ass y provided information on the metabolic state of the cells, while real-tim  
monitoring of im edanc  showed the biological st te of the cell culture  including growth, viability 
and adherence without using a tr cer. Previous measureme ts related to t is top c can ot be found 
in e literature. 
2. Results and Discussion 
Based on the TT assay, none of the excipients showed toxicity at 0.3% (w/v) concentration or 
below on human nasal epithelial cells. At 1% concentration, a highly and significantly reduced 
metabolic activity was measured by the colorimetric test of methylcellulose and the cyclodextrins 
(Figure 1). This concentration of the excipients was further studied in a kinetic experiment using 
impedance measurements. 
 
Figure 1. Toxicity of different excipients on RPMI 2650 cells measured by 3-(4,5-dimethyltiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) dye conversion assay. All values presented are means ± SD, 
n = 4. Significant differences compared to the values measured in control group are indicated as  
* p < 0.05; *** p < 0.001. 
The results of the real-time cell-analysis with excipients used at 1% concentration are shown in 
Figure 2. 
Triton X-100 immediately and irreversibly dropped the impedance of the cell layers, indicating 
cell death. Using this method, β- was toxic but α-cyclodextrin was not toxic on RPMI 2650 cells. 
Mannitol decreased the impedance of the layers, indicating opening of intercellular junctions. The 
effect of hyperosmotic mannitol on intercellular junctions has been already described for different 
barriers, including the blood-brain barrier [4]. The other additives showed no cytotoxicity by the 
kinetic measurement. Polyvinyl alcohol at 1% was not toxic in any of the tests, indicating its safety, 
which was already confirmed in animal studies [9]. A similar result was obtained for sodium 
hyaluronate. Our previous study also highlighted the safe use of nasal application of hyaluronate as 
mucoadhesive excipient in rats [5]. Based on the MTT assay, mannitol at 1% concentration had no 
effect on the viability of RPMI 2650 cells, but the decreased impedance implied some effects on the 
intercellular junctions [4]. In the case of the methylcellulose, the cell metabolic assay did not show cell 
Figure 1. Toxicity of different excipients on RPMI 2650 cells measured by 3-(4,5-dimethyltiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) dye conversion assay. All values presented are means ˘ SD,
n = 4. Significant differences compared to the values measured in control group are indicated as
* p < 0.05; *** p < 0.001.
The results of the real-time cell-analysis with excipients used at 1% concentration are shown in
Figure 2.
Triton X-100 immediately and irreversibly dropped the impedance of the cell layers, indicating cell
death. Using this method, β- was toxic but α-cyclodextrin was not toxic on RPMI 2650 cells. Mannitol
decreased the impedance of the layers, indicating opening of intercellular junctions. The effect of
hyperosmotic mannitol on intercellular junctions has been already described for different barriers,
including the blood-brain barrier [4]. The other additives showed no cytotoxicity by the kinetic
measurement. Polyvinyl alcohol at 1% was not toxic in any of the tests, indicating its safety, which was
already confirmed in animal studies [9]. A similar result was obtained for sodium hyaluronate.
Our previous study also highlighted the safe use of nasal application of hyaluronate as mucoadhesive
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excipient in rats [5]. Based on the MTT assay, mannitol at 1% concentration had no effect on the
viability of RPMI 2650 cells, but the decreased impedance implied some effects on the intercellular
junctions [4]. In the case of the methylcellulose, the cell metabolic assay did not show cell damages,
but the impedance measurement did. The observed high viscosity of 1% methylcellulose may affect
the endocytosis of MTT dye, the exocytosis of formazan crystals and maybe influenced the colorimetric
assay. In case of both assays β-cyclodextrin showed the most toxic among the tested additives.
This result was in agreement with the toxicity of cyclodextrins on Calu-3 epithelial cells [10].
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from Gedeon Richter Plc. (Budapest, Hungary), α- and β-cyclodextrins from Cyclolab Ltd. (Budapest,
Hungary), polyvinyl alcohol 27,000 from ISP Customer Service GmBH (Cologne, Germany) and
methylcellulose purchased from HARKE Pharma (Muelheim an der Ruhr, Germany). Stock solutions
were prepared by dissolving compounds Eagle’s minimal essential medium.
3.2. Methods
3.2.1. MTT Dye Assay
RPMI 2650 (ATCC cat. no. CCL 30) cells were grown in Eagle’s MEM supplemented with 10%
foetal bovine serum and 50 µg/mL gentamicin in a humidified 37 ˝C incubator with 5% CO2 [6,7].
The cells were cultured in 96-well plates coated with 0.05 % rat tail collagen. After treatments with the
excipients the cells were incubated with 0.5 mg/mL MTT solution for 3 h in CO2 incubator. The amount
of formazan crystals was dissolved in dimethyl-sulfoxide and determined by measuring of absorbance
at 570 nm with a microplate reader (Fluostar Optima, BMG Labtechnologies, Ortenberg, Germany).
The cell viability was expressed as the percentage of the MTT reduction by RPMI 2650 cells treated
with culture medium (negative control, 100 % viability).
3.2.2. Real-Time Impedance Measurement
Living cells were monitored by real-time cell electronic sensing (RTCA-SP, ACEA Biosciences,
San Diego, CA, USA) The device utilizes an electronic readout called impedance to non-invasively
quantify adherent cell proliferation and viability as used in our previous studies [7,8]. RPMI 2650
cells were seeded in 96-well plates containing gold microelectronic sensor arrays coated with rat-tail
collagen (0.05%) and grown at 37 ˝C in an incubator. Before measurements, cell-free medium was
used to determine the background impedance. Twenty-four hours later, the cells were treated with
additives. Impedance was measured before the treatment in every 5, and during the treatment in every
2 min. The normalized cell index is determined by the formula:
pRn´Rbq{15 (1)
where Rn is the impedance between cells and electrode, Rb is background impedance of the well with
the media alone.
3.2.3. Statistical Analyses
All data presented are means˘ SD. Experiments were performed at least 3 times with 4–8 parallel
samples. Values were compared using the analysis of variance followed by Dunnett tests (GraphPad
Prism 5.0 software, WaveMetrics Inc., Portland, OR, USA). Changes were considered statistically
significant at p < 0.05.
4. Conclusions
Because earlier published research works did not contain cytotoxicity tests, our aim was to
determined applicable concentrations of the frequently applied experiments in nasal formulation.
In conclusion of the results of MTT and impedance measurements, polyvinyl alcohol and sodium
hyaluronate at 1% concentrations can be safely used for nasal formulations. β-D-mannitol, α- and
β-cyclodextrins and methylcellulose are suggested to be used in 0.3% concentrations in nasal vehicles.
Choosing the excipients within the above mentioned concentrations appears promising for minimizing
toxicity. Also, there is a possibility to use them for local or systemic nasal drug development.
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